aibioChina Resources Pharmaceutical unit issues RMB900 million corporate bonds
Tickers 3320
A wholly owned subsidiary completed the second tranche of its 2026 corporate bonds in the PRC, RMB900 million at 1.48% per annum over three years.
Key facts
- Company
- China Resources Pharmaceutical Group Ltd. (HKEX: 3320)
- News type
- Debt Financing
- Primary source
- China Resources Pharmaceutical Group Limited announcement (2026-10-16)
China Resources Pharmaceutical Group Limited said on October 16, 2026 that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, completed the public issuance of the second tranche of its 2026 corporate bonds in the PRC. The announcement refers to an earlier announcement dated 16 April 2026 about the first tranche.
The second tranche was issued in a principal amount of RMB900 million, with a term of three years and a coupon rate of 1.48% per annum.
The net proceeds will be used for production expenditures, including repayment of corporate debts, replenishment of working capital, project development and operation expenditures, investments related to scientific and technological innovations, and other purposes that comply with applicable laws and regulations.
The announcement names no underwriter, placement agent or advisor for the bonds. Shareholders and potential investors were told to take care when dealing in the company's securities. The announcement was issued by order of the board and signed by the chairman, Mr. Bai Xiaosong.